Trading Information Summary - On July 11, 2025, the stock price of Yingke Medical (300677) closed at 26.78 yuan, down 0.37%, with a turnover rate of 3.63% and a trading volume of 168,700 shares, amounting to a total transaction value of 455 million yuan [1] - On the same day, the net inflow of main funds was 25.4 million yuan, while retail investors experienced a net outflow of 21.1 million yuan [3] Company Announcements Summary - Yingke Medical adjusted the conversion price of its convertible bonds from 3.39 yuan/share to 3.26 yuan/share, effective from July 11, 2025 [1][3] - The company completed the repurchase and cancellation of 4,504,300 shares, accounting for 0.6969% of the total share capital, reducing the total share capital from 646,326,180 shares to 641,821,880 shares [2][3] - Following the share cancellation, the shareholding ratio of the controlling shareholder, Liu Fangyi, increased from 35.85% to 36.10% [2] - The "Yingke Convertible Bonds" will mature on August 15, 2025, with a redemption price of 128 yuan per bond (including the last interest payment), and the last conversion date is also August 15, 2025 [2][3]

Group 1 - The core point of the announcement is that Yingke Medical Technology Co., Ltd. is reminding holders of its convertible bonds ("Yingke Convertible Bonds") about the upcoming expiration and conversion options [1][2][3] - The "Yingke Convertible Bonds" were issued on August 16, 2019, with a total amount of 470 million yuan, and are currently trading on the Shenzhen Stock Exchange under the code "123029" [1][2] - The conversion price for the bonds is set at 3.26 yuan per share, allowing bondholders to convert their bonds into company stock during the conversion period [1][2] Group 2 - The bonds will be redeemed at 128% of their face value, which amounts to 128 yuan per bond, including the last interest payment, within five trading days after the maturity date of August 15, 2025 [2][3] - The trading of "Yingke Convertible Bonds" was suspended on June 29, 2021, and will not resume before the end of the conversion period [2] - The company will publish announcements regarding the bond's maturity and delisting on the designated information disclosure website [3]

| 证券代码：300677 | 证券简称：英科医疗 | 公告编号：2025-099 | | --- | --- | --- | | 债券代码：123029 | 债券简称：英科转债 | | 英科医疗科技股份有限公司 关于英科转债即将到期暨赎回的第一次提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 特别提示： 1、"英科转债"到期日：2025 年 8 月 15 日； 2、"英科转债"到期兑付价格：128 元人民币/张（含最后一期 利息）； 3、"英科转债"最后转股日：2025 年 8 月 15 日； 4、"英科转债"最后交易日为 2021 年 6 月 28 日，已于 2021 年 6 月 29 日停止交易。在停止交易后、转股期结束前（即 2021 年 6 月 29 日至 2025 年 8 月 15 日），"英科转债"持有人仍可以依据约定 的条件，将"英科转债"转换为公司股票，目前转股价格为人民币 3.26 元/股； 5、截至 2025 年 8 月 15 日收市后仍未转股的"英科转债"将被 强制赎回；本次赎回完成后，"英科转债"将在深圳证券交易所摘牌。 ...

Summary of Key Points Core Viewpoint The announcement details the completion of a share buyback and cancellation by Yingke Medical Technology Co., Ltd., which has resulted in a change in the shareholding structure of the company, particularly affecting the stake of the controlling shareholder. Group 1: Share Buyback Overview - The company repurchased 4,504,300 shares, which accounted for approximately 0.6969% of the total share capital before the cancellation [1][2]. - The buyback was conducted using a budget of between RMB 100 million and RMB 200 million, with a maximum repurchase price of RMB 33.03 per share [1]. - The buyback was intended for employee stock ownership plans and/or equity incentives, but the purpose was later changed to reduce registered capital [1][2]. Group 2: Completion of Share Cancellation - The cancellation of the repurchased shares was confirmed to be completed on July 10, 2025, resulting in a reduction of the total share capital from 646,326,180 shares to 641,821,880 shares [2]. - The shareholding structure post-cancellation shows that the proportion of restricted shares increased slightly, while the proportion of unrestricted shares decreased [2]. - The controlling shareholder, Liu Fangyi, increased his shareholding from 35.85% to 36.10% following the cancellation [1][2]. Group 3: Impact on Company Structure - The share buyback and cancellation will not materially affect the company's financial status or operational results, nor will it harm the interests of minority investors [2]. - The company will proceed with necessary legal registrations and amendments to its articles of association following the completion of the share cancellation [3].

证券代码：300677 证券简称：英科医疗 公告编号：2025-097 2、经中国证券登记结算有限责任公司深圳分公司确认，公司本 次回购股份注销事宜已于 2025 年 7 月 10 日办理完成。 3、因注销回购股份导致公司总股本发生变动，公司控股股东、 实际控制人刘方毅先生持有公司股份比例由 35.85%增加至 36.10%。 一、回购股份情况概述 1、公司于 2023 年 7 月 13 日召开第三届董事会第十五次会议和 第三届监事会第十四次会议，审议通过了《关于公司回购股份方案的 议案》，同意公司使用不低于人民币 10,000 万元（含本数）且不超过 人民币 20,000 万元（含本数）的自有资金，以集中竞价交易的方式回 购部分公司股份（人民币普通股（A 股）股票），用于实施员工持股 计划及/或股权激励。回购价格不超过人民币 33.03 元/股（含本数）， 回购股份的数量和金额以回购期限届满时实际回购的股份数量和金 额为准。回购股份的实施期限为自公司第三届董事会第十五次会议审 议通过本次回购股份方案之日起不超过 12 个月。具体内容详见公司 分别于 2023 年 7 月 13 日、2023 年 7 月 17 ...

本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 特别提示： | | | 债券代码：123029 债券简称：英科转债 调整前转股价格：人民币 3.39 元/股 调整后转股价格：人民币 3.26 元/股 转股价格调整生效日期：2025 年 7 月 11 日 | 证券简称：英科医疗 | 公告编号：2025-098 | | --- | --- | | 债券简称：英科转债 | | | 证券代码：300677 债券代码：123029 | | 英科医疗科技股份有限公司 关于部分回购股份注销调整"英科转债"转股价格 的公告 本次调整可转债转股价格不涉及暂停转股事项 一、关于可转换公司债券转股价格调整的相关规定 英科医疗科技股份有限公司（以下简称"公司"）公开发行了 470 万张可转换公司债券（债券简称：英科转债，债券代码：123029）并 于 2019 年 9 月 10 日上市。根据《山东英科医疗用品股份有限公司创 业板公开发行可转换公司债券募集说明书》及中国证券监督管理委员 会关于可转换公司债券发行的有关规定，当公司发生派送股票股利、 转增股本、增发新股（不包括因本次发行的 ...

Core Viewpoint - The company, Yingke Medical (300677), has announced the cancellation of 4.5043 million shares repurchased, which accounts for 0.6969% of the total share capital before the cancellation, amounting to 646 million shares [1] Summary by Relevant Sections - Share Cancellation Details - The total number of shares canceled is 4.5043 million [1] - The total share capital will decrease from 646 million shares to 642 million shares after the cancellation [1] - Impact on Shareholding Structure - Following the cancellation, the shareholding percentage of the controlling shareholder and actual controller, Mr. Liu Fangyi, will increase from 35.85% to 36.10% [1] - Financial and Operational Impact - The share cancellation will not have a substantial impact on the company's financial status or operational results [1] - There will be no change in the controlling shareholder or actual controller, and the company's equity distribution remains compliant with listing requirements [1]

Core Insights - The core viewpoint of the article emphasizes the significant advancements made by the company in its environmental, social, and governance (ESG) practices, particularly through innovation and green initiatives. Group 1: Innovation and R&D Investment - In 2024, the company increased its R&D investment to 398 million yuan, a 40% increase from 284 million yuan in 2023 [1][3] - The number of R&D personnel rose from 972 in 2023 to over 1200, accounting for more than 10% of the total workforce [3] - The company launched 55 new products in the past year, a 197% increase, covering three core areas: medical consumables, health care devices, and medical care [4] Group 2: Environmental Impact and Green Initiatives - The carbon emissions per glove decreased to 20.41 grams, a reduction of 20.70% compared to the previous year [4] - Water consumption per glove was reduced to 0.21 liters, down 11.02% from the previous year [4] - The company is investing in clean energy, with wind power infrastructure expected to be operational by 2025 [6] Group 3: Social Responsibility and Community Engagement - The company donated over 300 wheelchairs to hospitals and communities, contributing to the equitable distribution of medical resources [8][10] - It has committed over 75.82 million yuan to social welfare since implementing its corporate social responsibility initiatives [10] - The company supports employee development with a 100% training coverage rate and an annual investment of 1.4914 million yuan in skills enhancement [8] Group 4: Corporate Governance and Supply Chain Management - The company has optimized its governance structure, with all seven board members possessing extensive industry knowledge [12] - It is building a sustainable supply chain ecosystem through strict supplier evaluation standards and capacity-building initiatives [12][15] - The company aims to reduce carbon emissions per glove by 25% by 2030 and achieve carbon neutrality in its operations by 2025 [15]

Core Points - The document outlines the procedures and regulations for the resignation of directors and senior management at Yingke Medical Technology Co., Ltd, aiming to maintain corporate governance stability and protect the rights of the company and its shareholders [1][2]. Chapter Summaries Chapter 1: General Provisions - The regulations are established based on relevant laws and the company's articles of association to standardize the resignation process of directors and senior management [1]. Chapter 2: Resignation Circumstances and Procedures - Directors can resign before their term ends by submitting a written resignation report, which becomes effective upon receipt by the company, and the company must disclose this within two trading days [2]. - If a director resigns and it results in the board falling below the legal minimum number of members, the director must continue to fulfill their duties until a new director is appointed [2]. - The company must complete the election of a new director within sixty days after a resignation to ensure compliance with legal and regulatory requirements [2]. - Senior management can also resign before their term ends, with specific procedures outlined in their labor contracts [2]. Chapter 3: Handover Procedures and Obligations - Resigning directors and senior management must complete handover procedures within five working days after their resignation, including transferring company seals and all relevant documents [3]. - If there are outstanding public commitments, the company can require a written fulfillment plan from the resigning personnel [3]. Chapter 4: Management of Shares Held by Resigning Directors and Senior Management - Resigning directors and senior management are prohibited from transferring their shares within six months of resignation [4]. - There are restrictions on the amount of shares that can be sold during their term and after resignation, ensuring compliance with relevant regulations [4]. Chapter 5: Accountability Mechanism - The board will review and determine accountability measures if a resigning director or senior management fails to fulfill commitments or obligations [5]. - Individuals can appeal the board's decisions regarding accountability within fifteen days [5]. Chapter 6: Supplementary Provisions - Any matters not covered by these regulations or conflicting with national laws will be governed by the relevant laws and the company's articles of association [6].

Core Points - The company is established as a joint-stock limited company in accordance with the Company Law of the People's Republic of China and other relevant regulations [1][2] - The registered capital of the company is RMB 641.700369 million [1] - The company aims to enhance product quality and develop new products using advanced technology and scientific management methods, thereby improving economic benefits for investors [3] Company Structure - The company is a permanent joint-stock limited company with the chairman serving as the legal representative [2] - The company’s assets are divided into equal shares, and shareholders are liable for the company's debts only to the extent of their subscribed shares [2][3] - The company has established a party organization to conduct activities in accordance with the Communist Party of China [3] Business Scope - The company’s business scope includes the production and sale of medical devices, sanitary products, and disposable medical supplies, among others [3][4] - The company is also involved in the manufacturing of rubber and plastic products, as well as the sale of various medical and daily-use products [3][4] Share Issuance - The company issues shares in the form of stocks, adhering to principles of openness, fairness, and justice [4][5] - The total number of shares issued by the company is 641.700369 million, all of which are ordinary shares [4][5] Shareholder Rights and Responsibilities - Shareholders have rights to dividends, voting, and participation in company meetings, as well as obligations to comply with laws and regulations [12][40] - The company’s shareholders are prohibited from withdrawing their capital except in legally specified circumstances [40] Governance and Decision-Making - The company’s governance structure includes a board of directors and a shareholder meeting, which are responsible for major decisions such as capital increases, mergers, and amendments to the articles of association [18][20] - Shareholder meetings can be called by the board or by shareholders holding more than 10% of the shares [49][54] Financial Management - The company is restricted from providing financial assistance for the acquisition of its shares, except under specific conditions approved by the board [5][6] - The company can increase its capital through various methods, including issuing new shares or converting bonds into shares [6][7]